Dendritic Cell Based Therapy of Renal Cell Carcinoma

NCT00197860 ↗

Phase 1/2 Completed 40 enrolled Inge Marie Svane

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to show if vaccination with autologous dendritic cells pulsed with peptides or tumor lysate in combination with adjuvant cytokines can induce a measurable immune response in patients with metastatic renal cell carcinoma, and to evaluate the clinical effect (objective response rate) of the vaccination regime.

Timeline

Start: 2004-09
Primary completion: 2009-12
Completion: 2010-10

Publications

Background Svane IM, Pedersen AE, Johnsen HE, Nielsen D, Kamby C, Gaarsdal E, Nikolajsen K, Buus S, Claesson MH. Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother. 2004 Jul;53(7):633-41. doi: 10.1007/s00262-003-0493-5. Epub 2004 Feb 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DC vaccine	Vaccine	5e+06 cells	Intravenous
Background	Thymalfasin	Peptide	1.6 mg	Subcutaneous
Background	aldesleukin	Protein / enzyme biologic	2e+06 iu	Subcutaneous

Dendritic Cell Based Therapy of Renal Cell Carcinoma

Summary

Timeline

Publications

Drugs

Indications